Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Johnson & Johnson single-shot COVID-19 vaccine: A real world evidence study

Next Previous
X
Search
Trial Profile

Efficacy of Johnson & Johnson single-shot COVID-19 vaccine: A real world evidence study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ad26.COV2 S (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 Oct 2021 According to a Johnson & Johnson media release, the U.S. FDA has issued Emergency Use Authorization for a booster dose of the Ad26.COV2-S vaccine for adults aged 18 and older at least two months following primary vaccination with Ad26.COV2-S vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine. The Johnson & Johnson booster shot will be the same formulation and dosage as the primary shot.
    • 15 Oct 2021 According to a Johnson & Johnson media release, the study is conducted from March to July 31, 2021, and recently extended to August 31, 2021.
    • 15 Oct 2021 According to a Johnson & Johnson media release, the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 19-0 to recommend Emergency Use Authorization (EUA) for a booster dose of COVID-19 vaccine for adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine, based on data from this and large and robust real-world evidence study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top